Prostate Cancer - Results from #980

REVIEW UroToday

Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer, "Beyond the Abstract," by Warren A. Chow, MD, FACP November 8, 2012

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: A Hellenic oncology research group multicenter phase II study, "Beyond the Abstract," by N. Kentepozidis November 7, 2012

Criteria for errors in prostate-specific antigen diagnostics, "Beyond the Abstract," by Stefan Buntrock, MD, FEBU November 6, 2012

Complementary and alternative medicines in prostate cancer: From bench to bedside? "Beyond the Abstract," by Samuel Klempner, MD November 5, 2012

Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy, "Beyond the Abstract," by Drew Moghanaki, MD November 2, 2012

Does transrectal color Doppler ultrasound improve the diagnosis of prostate cancer? "Beyond the Abstract," by Alessandro Del Rosso, MD October 31, 2012

Diffusion tensor magnetic resonance tractography of the prostate: Feasibility for mapping periprostatic fibers, "Beyond the Abstract," by David S. Finley, MD and Benjamin Ellingson, PhD October 30, 2012

Safety and preliminary efficacy analysis of the mTOR inhibitor Ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer, "Beyond the Abstract," by Robert J. Amato, DO October 30, 2012

Successful treatment of advanced metastatic prostate cancer following chemotherapy based on molecular profiling, "Beyond the Abstract," by Charles E. Myers, MD October 25, 2012

Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy, "Beyond the Abstract," by Simone Albisinni, MD October 23, 2012

Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy, "Beyond the Abstract," by Sergey Shikanov, MD October 22, 2012

Radical prostatectomy in clinically localized high-risk prostate cancer: Outcome of 231 consecutive patients, "Beyond the Abstract," by M. Andreas Røder, et al. October 18, 2012

Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy, "Beyond the Abstract," by Mark K. Buyyounouski, MD, MS, et al October 15, 2012

Urethroplasty after radiation therapy for prostate cancer, "Beyond the Abstract," by Allison S. Glass, MD; Jack W. McAninch, MD; James McGeady, MD; and Benjamin N. Breyer, MD, MAS October 11, 2012

IQGAP2, A candidate tumour suppressor of prostate tumorigenesis, "Beyond the Abstract," by Damu Tang, PhD October 10, 2012

Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer, "Beyond the Abstract," by Robert Amato, DO and Mika Stepankiw, MS October 9, 2012

Effects of lysophosphatidic acid on calpain-mediated proteolysis of focal adhesion kinase in human prostate cancer cells, "Beyond the Abstract," by Kathryn E. Meier, PhD October 8, 2012

A close surgical margin after radical prostatectomy is an independent predictor of recurrence, "Beyond the Abstract," by Chin-Lee Wu, MD, PhD October 5, 2012

RhoA as a mediator of clinically relevant androgen action in prostate cancer cells, "Beyond the Abstract," by Hannelore V. Heemers, PhD October 4, 2012

IRX4 at 5p15 suppresses prostate cancer growth through the interaction with vitamin D receptor, conferring prostate cancer susceptibility, "Beyond the Abstract," by Hidewaki Nakagawa, MD, PhD September 28, 2012

Page 50 of 57